F
FibroBiologics, Inc. (FBLG)
NCM – Real Time Price. Currency in USD
0.20
-0.02 (-10.64%)
At close: Mar 27, 2026, 4:00 PM EDT
0.20
+0.00 (1.17%)
After-hours: Mar 27, 2026, 7:49 PM EDT
Get all premium features to the best stock analysis tool
NCM – Real Time Price. Currency in USD
0.20
-0.02 (-10.64%)
At close: Mar 27, 2026, 4:00 PM EDT
0.20
+0.00 (1.17%)
After-hours: Mar 27, 2026, 7:49 PM EDT
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company’s product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
| Name | Position |
|---|---|
| Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
| Mr. Peter O'Heeron | Founder, Chairperson & CEO |
| Mr. Ruben A. Garcia J.D. | General Counsel |
| Date | Type | Document |
|---|---|---|
| 2026-03-13 | 10-K/A | fblg-20251231.htm |
| 2026-03-06 | 8-K | fblg-20260304.htm |
| 2026-01-02 | 8-K | fblg-20251230.htm |
| 2025-12-29 | DEFA14A | add_proxy_mtrls_december.htm |
| 2025-12-23 | S-1 | forms-1.htm |
| 2025-12-18 | DEF 14A | fblg-20251218.htm |
| 2025-12-16 | D | |
| 2025-12-15 | 8-K | fblg-20251214.htm |
| 2025-12-03 | D | |
| 2025-11-19 | 8-K | fblg-20251118.htm |